Companies › HitGen
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HG146 | – | Phase 2 | Adenoid Cystic Carcinoma | Dec 2028 |
| HG381 | – | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04998422 | HG381 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT06781567 | HG146 | Phase 2 | Adenoid Cystic Carcinoma | Oncology | Dec 2028 |
No annotated target.
–
Zhejiang Hisun Pharmaceutical Tianjin ConjuStar Biologics Advenchen Laboratories OSE Immunotherapeutics Teligene US
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.